8-K: Green Thumb Industries Reports Q1 2026 Results

Green Thumb Industries Inc. announced first quarter 2026 revenue of $300.2 million, a 7.4% increase year-over-year, with normalized EBITDA of $93.5 million.

Summary

• Green Thumb Industries Inc. reported first quarter 2026 revenue of $300.2 million, a 7.4% increase compared to the prior year period.
• The company achieved a normalized EBITDA of $93.5 million, representing 31.2% of revenue.
• GAAP net income was $15.4 million, or $0.07 per share, an increase from $8.3 million in the prior year.
• Cash flow from operations was $76.0 million.
• The company repurchased approximately 6.0 million subordinate voting shares for $33.3 million during the quarter.
• Subsequent to the quarter, an additional 7.4 million shares were repurchased, bringing year-to-date repurchases to 13.4 million shares for $77.7 million.
• The company's cash balance at the end of the quarter was $344.5 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with solid revenue growth, improved profitability metrics (Normalized EBITDA), and significant share repurchases, further bolstered by the favorable federal rescheduling of medical cannabis.

Positives

• Revenue increased by 7.4% to $300.2 million in the first quarter of 2026 compared to the prior year.
• Normalized EBITDA reached $93.5 million (31.2% of revenue), an increase from $85.2 million (30.5% of revenue) in the prior year.
• GAAP net income rose to $15.4 million ($0.07 per share) from $8.3 million ($0.04 per share) in the prior year.
• Cash flow from operations was strong at $76.0 million.
• The company increased its syndicated credit facility by $50.0 million.
• Conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations.
• Submitted registration applications with the U.S. DEA following the federal rescheduling of medical cannabis to Schedule III.

Negatives

• Gross profit margin decreased to 47.9% from 51.3% in the prior year period, primarily due to brand license fees and price compression.
• Consumer Packaged Goods' gross revenue decreased by 1.6% year-over-year, impacted by price compression and competition.
• First quarter 2026 same store comparable sales decreased by 0.5% on a base of 100 stores.

Risks

• Cannabis remains illegal under U.S. federal law, and enforcement of cannabis laws could change.
• Future state regulation of cannabis is uncertain.
• The company may face limitations on ownership of cannabis licenses.
• As a cannabis business, the company is subject to applicable anti-money laundering laws and regulations and has restricted access to banking and other financial services.
• The company faces intense competition from the illicit market and hemp products.
• The company faces unfavorable tax treatment and may incur significant tax liability.
• The company faces risks related to its products, including potential recalls and unfavorable publicity.
• The company relies on third-party software providers and is vulnerable to cyber-attacks and security breaches.

Future Outlook

The company's management expresses strong conviction in Green Thumb's future, particularly in light of the federal rescheduling of medical cannabis to Schedule III, which is expected to provide meaningful flexibility for reinvestment. They remain focused on disciplined execution and building for the future, aiming to meet rising consumer demand responsibly.

Management Comments

• "The Green Thumb team delivered a strong start to 2026, with first quarter revenue of $300 million, Normalized EBITDA of $94 million and cash flow from operations of $76 million."
• "The recent federal action to reschedule medical cannabis from Schedule I to Schedule III is a historic step forward for our business, for investors, and for the country."
• "With medical cannabis now rescheduled, the resulting Section 280E relief for the medical portion of our business creates meaningful flexibility to reinvest in our operations, our people, and the communities we serve."
• "Consumer demand for THC continues to rise, and rescheduling helps create a more practical framework for companies like Green Thumb to meet that demand responsibly while continuing to grow and scale our business."

Industry Context

StockSavvy.ai notes that Green Thumb Industries' Q1 2026 results reflect the evolving landscape of the cannabis industry, particularly with the federal rescheduling of medical cannabis to Schedule III. This move is anticipated to alleviate tax burdens (Section 280E) and create opportunities for reinvestment, potentially benefiting companies with established operations like Green Thumb. The reported revenue growth and strong EBITDA margins indicate resilience amidst market challenges such as price compression and competition.

Comparison to Industry Standards

• Green Thumb's normalized EBITDA margin of 31.2% is a key performance indicator in the cannabis sector, where margins can vary significantly due to regulatory costs and market dynamics.
• The company's revenue growth of 7.4% should be compared against other multi-state operators (MSOs) in the U.S. cannabis market to assess relative performance.
• The share repurchase program, totaling approximately $200.0 million since September 2023, indicates a capital allocation strategy focused on returning value to shareholders, a common practice among mature companies in various industries.

Related Party Transactions

• Income associated with the Company's related party equity method investment was $6.5 million in Q1 2026.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, share repurchases, and potential future growth driven by regulatory changes.
• Employees: Potential for reinvestment in operations and people, as mentioned by management.
• Patients and Consumers: Continued service and potential for improved product availability and responsible growth.
• Regulators: Compliance with evolving state and federal regulations is critical.

Next Steps

• Continue to focus on disciplined execution and building for the future.
• Reinvest in operations, people, and communities enabled by potential Section 280E relief.
• Serve patients and consumers while maintaining momentum for broader federal reform and legalization.
• Continue to monitor and adapt to evolving regulatory landscapes and market competition.

Key Dates

Recommendation

While the results show positive growth and improved profitability, the slight decline in same-store sales and ongoing risks associated with the cannabis industry (federal illegality, regulatory uncertainty, competition) suggest a 'hold' recommendation. The positive impact of cannabis rescheduling is significant but its full realization will take time. Investors should monitor execution and competitive pressures.

Keywords

Green Thumb Industries, GTI, Cannabis, 8-K, Financial Results, EBITDA, Revenue, RISE Dispensaries